Table 2 Review of studies evaluating patients treated with cranial radiation and ipilimumab
From: Ipilmumab and cranial radiation in metastatic melanoma patients: a case series and review
N | Median overall survival (mos) | Landmark survival | Steroid use | Timing issues | Radiation necrosis requiring surgery | |
|---|---|---|---|---|---|---|
Kiess et al. [10] | 46 | 12.4 | 1 yr OS 40–65 % depending on timing of ipi | Routine use of ppx steroids | SRS before or during ipi associated with improved OS | 5 patients |
Knisely et al. [19] | 27 | 21.3 | 2 yr OS 47 % | Not reported | SRS before ipi associated with trend towards improved survival | 3 patients |
Mathew et al. [11] | 25 | 5a | 6 mos OS 56 % | Routine use of ppx steroids | Not reported | 0 |
Schoenfeld et al. (current study) | 16 | 14.4 | 1 yr OS 54 % | No routine use of ppx steroids | SRS before ipi associated with better survival | 0 |
Shoukat et al. [20] | 11 | 28.3 | 1 yr OS 67 % | Not reported | Not reported | 3 patientsb |
Tazi et al. [21] | 10 | 29.3 | 2 yr OS 58 % | Not reported | All patients received SRS before or during ipi | Not reported |